Compare Lemonade Inc (LMND) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lemonade Inc vs Stryker Corporation — how do they compare? Lemonade Inc trades at $67.24 (market cap $5.18B), while Stryker Corporation trades at $315.29 (market cap $122.35B). The key difference: Stryker Corporation is far larger — about 23.6× Lemonade Inc's market cap, and Stryker Corporation pays a 1% dividend while Lemonade Inc pays none. Which is the better fit depends on your goals.
| LMND | SYK | |
|---|---|---|
Market Cap | $5.18B | $122.35B |
Sector | Financials | Technology |
52-Week High | $96.57 | $403.53 |
52-Week Low | $36.28 | $282.58 |
Enterprise Value | $5.01B | $134.10B |
Dividend Yield | — | 1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lemonade (LMND) trades at $67.47, up 0.43% on the day, with a bullish technical signal from moving averages and RSI near oversold levels. Revenue growth is accelerating, reaching $738 million in 2025, while net losses are narrowing to -$166 million. Recent news highlights expansion into new states and reinsurance program improvements, supporting optimism for future profitability.
The outlook is mixed: strong top-line growth and path to EBITDA positivity offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus targets $69.60, with 33% buy ratings, reflecting cautious optimism amid execution challenges in the competitive insurance sector.
Stryker (SYK) trades at $319.14, down 0.23% on the day, with a bearish technical signal despite strong fundamentals. The company reported $25.12B revenue and $3.25B net income for 2025, maintaining robust profitability with 63.83% gross margins and 13.21% net margins. Recent Q1 2026 earnings missed expectations due to a cybersecurity disruption, but management maintained full-year guidance. Analyst consensus remains strongly bullish with a $388.44 price target and 74% buy ratings.
The stock presents a compelling opportunity for long-term investors given its strong fundamentals and innovation pipeline, though near-term technical weakness and competitive pressures warrant caution. Upside potential exists from continued Mako robotics adoption and market share gains, while risks include cybersecurity vulnerabilities and integration challenges from acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
